Piper Sandler analyst Sumeet Mody downgrades Virtus Investment (NASDAQ:VRTS) from Overweight to Neutral.
Checkpoint Therapeutics Announces Publication Of Cosibelimab Pivotal Trial Results In The Journal For ImmunoTherapy Of Cancer
Cosibelimab is the first PD-L1–blocking antibody to demonstrate a robust, durable and clinically meaningful objective response, and a manageable safety profile, in patients with metastatic cutaneous squamous cell